A cationic TAT peptide inhibits Herpes simplex virus type 1 infection of human corneal epithelial cells.
Larsen
Inna V
IV
Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI 53706, USA.
Brandt
Curtis R
CR
D000998:Antiviral Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000633:toxicity; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D019573:Epithelium, Corneal / Q000821:virology*; D015696:Gene Products, tat / Q000008:administration & dosage / Q000494:pharmacology* / Q000633:toxicity; D006561:Herpes Simplex / Q000188:drug therapy* / Q000821:virology; D018259:Herpesvirus 1, Human / Q000187:drug effects*; D006801:Humans; D010446:Peptide Fragments / Q000627:therapeutic use*; D010455:Peptides / Q000627:therapeutic use*; D013997:Time Factors; D018675:Toxicity Tests; D014779:Virus Replication / Q000187:drug effects; D001616:beta-Galactosidase / Q000378:metabolism
D000998:Antiviral Agents; D015696:Gene Products, tat; D010446:Peptide Fragments; D010455:Peptides; C556657:TAT-Cd(0) peptide; D001616:beta-Galactosidase